Richard Warren is Professor of Dermatology and Therapeutics and Honorary Consultant Dermatologist. He graduated from Liverpool University with a first class honours degree in Pharmacology and gained his Medical degree, with honours, one year later. He was awarded The J Hill Abram prize - highest mark in Medicine and the Reginald Dora Goodrick prize - highest mark in Surgery. His work in Dermatology has focussed on: pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility to psoriasis and more recently biological therapies and their use in the treatment of psoriasis. For his work into the pharmacogenetics of methotrexate he has received national and international awards from the British Association of Dermatologists (BAD) and American Academy of Dermatology.  He is widely published in the field of Dermatology with numerous abstracts, papers and book contributions including The Lancet, Nature Genetics and The Journal of Investigative Dermatology. He is currently the EU Editor in Chief for the journal Dermatology and Therapy.  He has been an invited plenary speaker at major national and international dermatology meetings and is a member of The International Psoriasis Council. He currently chairs the BAD guideline group for methotrexate and is a member of the BAD biologics committee and research subcommittee. In 2012 he was the expert panel member on the National Institute for Health and Clinical Excellence guideline group for psoriasis.  He is co-lead of one of the two workstreams involved in the successful funding from the Medical Research Council stratified medicine grant  (Value £7 million) - Psoriasis Stratification to Optimise Relevant Therapies (PSORT).  He is the Chief Investigator on the largest psoriasis study currently running in the UK, known as SIGNATURE, investigating a new biological therapy for the treatment of severe psoriasis. He is the principle investigator at Salford Royal NHS Foundation Trust for BADBIR, a large scale pharamcovigilance study, and led the team to the award for highest recruiting centre in 2012.  He co-established a clinic for patients with severe psoriasis and psoriatic arthritis in 2010 with Dr Hector Chinoy which has received wide acclaim and is used as a national exemplar.

Richard Warren is a Clinical Senior Lecturer and Honorary Consultant Dermatologist funded by the National Institute For Health Research. He was previously funded by the Medical Research Council

Current research programmes include:

Stratified medicine

Pharmacovigilance

Psoriasis genetics

Clinical Trials

Funding Medical Research Council, British Skin Foundation, Psoriasis Association, NIHR, Industry Collaborations

Dr Warren currently supervises 4 PhD students, 2 of whom are funded by the Medical Research Council. The topics of their PhDs range from clinical studies of psoriasis phenotypes, the genetic basis of psoriasis, predictors of drug treatment response for psoriasis and safety of new therapies used to treat psoriasis. 

Dr Warren is a prolific teacher of undergraduates and gives regular lectures and clinical teaching sessions to medical students.

He has lectured widely around the world frequently recieving exceptional feedback for the educational component of his lectures.

Dr Warren has built wide ranging colloboartions around  the UK and internationally.

Key Colloborators in Manchester include Professor Anne Barton, Professor Jane Worthington - psoriasis genetics.

Professor Graeme Black - investigations into palmoplantar pustulosis.

Professor Darren Ashcroft - investigations into the safety of biological therapies.

Dr Hector Chinoy - drug immunogenecity.

Nationally Professor Jonathan Barker (KCL), Professor Frank Nestle (KCL),  Professor Catherine Smith (KCL), Professor Nick Reynolds (Newcastle), Professor David Burden (Glasgow) - stratified medicine and investigations into the safety of biological therapies.

Internationally Professor Alan Menter (Baylor, Texas) - psoriasis phenotypes; Professor Kristian Reich (Hamburg, Germany) -Clinical Trials, Professor Brian Kirby (Dublin) psoriasis genetics.